102P Sustained response and long-term therapeutic benefits beyond treatment cessation in NSCLC relapsed-patients treated with ateganosine and ICI in the THIO-101 trial

Despite advancements in first-line treatments, long-term survival for advanced non-small cell lung cancer (NSCLC) remains suboptimal, with only 28% of patients surviving beyond five years. Treatment options for immune checkpoint inhibitor (ICI)-resistant patients are limited. Ateganosine (THIO, 6-thio-dG), a telomere-targeting agent, modifies telomeres in cancer cells, including circulating tumor cells (CTCs), confirming its mechanism of action and demonstrating efficacy independent of PD-L1 expression.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106409
Primary Topic
Telomeres, Telomerase, and Senescence
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

102P Sustained response and long-term therapeutic benefits beyond treatment cessation in NSCLC relapsed-patients treated with ateganosine and ICI in the THIO-101 trial

Marek Kotlarski, Rodryg Ramlau, Szabolcs Soter, Tibor Csőszi et al.
ESMO Open
Telomeres, Telomerase, and Senescence
article

102P Sustained response and long-term therapeutic benefits beyond treatment cessation in NSCLC relapsed-patients treated with ateganosine and ICI in the THIO-101 trial

Marek Kotlarski, Rodryg Ramlau, Szabolcs Soter, Tibor Csőszi, Constantin Volovăț, Veronika Müller, Victor Zaporojan, Oleg Tudos, Matthew Failor, Mariola Kowal-Rosinska, T. Nagy, M. Vidotto Mitsunaga, I. Mender, M.R. Girotti, T. Jankowski, F. Amurariti, R.D. Bobora, V. Vitoc, D-E. Sirbu, S. Gryaznov
article en

Abstract

Despite advancements in first-line treatments, long-term survival for advanced non-small cell lung cancer (NSCLC) remains suboptimal, with only 28% of patients surviving beyond five years. Treatment options for immune checkpoint inhibitor (ICI)-resistant patients are limited. Ateganosine (THIO, 6-thio-dG), a telomere-targeting agent, modifies telomeres in cancer cells, including circulating tumor cells (CTCs), confirming its mechanism of action and demonstrating efficacy independent of PD-L1 expression.

ESMO OpenVol. 11
Semmelweis University (HU), Poznan University of Medical Sciences (PL), Medical University of Lublin (PL), West University of Timişoara (RO), Department of Biotechnology (IN), Spitalul Clinic Judeţean de Urgenţă "Pius Brînzeu" Timişoara (RO), EP Analytics (United States) (US), National Institute of Oncology (HU), Camera de Comerț Industrie și Agricultură Timișoara (RO), Lublin Oncology Center (PL), 1 Military Clinical Hospital with Outpatient Clinic (PL), Institute e-Austria Timisoara (RO), Romanian Institute of Science and Technology (RO), Athens Euroclinic (GR), Optivia Biotechnology (United States) (US), Országos Korányi Tbc és Pulmonológiai Intézet (HU), Universidad Argentina de la Empresa (AR)
Good health and well-being
Openalex Percentile: Top 18%
Telomeres, Telomerase, and Senescence
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.